ArticleDevelopment (Cambridge, England)2019
CD40 forward signalling is a physiological regulator of early sensory axon growth.
Article in Development (Cambridge, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Genes in Axonal Regeneration.Molecular neurobiology · 2024Review
- CD40-CD40L in Neurological Disease.International journal of molecular sciences · 2022Review
- CD40L/CD40 bidirectional signaling is a major regulator of neuronal morphology in the developing nervous system.Neural regeneration research · 2021Article
- Article
- Neuregulin-4 contributes to the establishment of cutaneous sensory innervation.Developmental neurobiology · 2021Article
- How CD40L reverse signaling regulates axon and dendrite growth.Cellular and molecular life sciences : CMLS · 2021Article
- Association of distinct type 1 bone morphogenetic protein receptors with different molecular pathways and survival outcomes in neuroblastoma.Neuronal signaling · 2020Article
- CD40L reverse signaling suppresses prevertebral sympathetic axon growth and tissue innervation.Developmental neurobiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Multiple members of the tumour necrosis factor superfamily (TNFSF) regulate the growth and branching of neural processes late in development, when neurons are establishing and refining connections. Here, we present the first evidence that a TNFSF member acts much earlier in development, when axons are growing to their targets. CD40L transiently enhanced axon growth from embryonic mouse DRG neurons cultured at this early stage. Early spinal nerves of embryos lacking the CD40L receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.